Gentian has together with research partners presented two posters related to the value of plasma and serum calprotectin in the management of COVID-19 patients at the AACC 2020. The results presented at the AACC conference show elevated levels of calprotectin in plasma/serum in patients with severe form of COVID-19. This suggests that calprotectin can be a valuable biomarker for prediction of mortality and need for mechanical ventilation. Both studies have used Gentian’s calprotectin immunoassay GCAL® for measurement of calprotectin in plasma and serum.
360Dx, a dedicated newsroom that covers emerging economic and technological trends in the clinical diagnostic market, has caught interest in the utility of calprotectin as a tool for risk assessment and prediction of clinical deterioration in COVID-19 patients.
360Dx has recently published an article that focuses on the recent results from the two AACC posters, confirming the value of calprotectin in severe COVID-19 disease. In the same article they also emphasises GCAL® 's (Gentian’s plasma and serum calprotectin assay) advantages being a particle-enhanced turbidimetric immunoassay (PETIA), compared to conventional enzyme-linked immunosorbent assays (ELISA).
Read the full article Studies Demonstrate Use of Gentian Calprotectin Test to Triage COVID-19 Patients with information from the two poster and more insights from Gentian's VP Clinical Affairs, Dr. Aleksandra Mandic Havelka and one of the co-author of one of the posters Dr. Luis García de Guadiana-Romualdo from the Hospital Universitario Santa Lucía in Cartagena, Spain.
Do you want to know more about our calprotectin and COVID-19 or our GCAL® Immunoassay? If yes, please fill out the form below or send an email to marketing@gentian.com and our Product Manager for GCAL® will contact you shortly.